Steigerwald, Gordon & Koch Inc. Bristol Myers Squibb CO Transaction History

Steigerwald, Gordon & Koch Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 17, 2023	BUY	$68.48 - $81.09 $193,387 - $228,998	2,824 New	2,824 $0
Q2 2022 Jul 14, 2022	BUY	$72.62 - $79.98 $201,230 - $221,624	2,771 New	2,771 $213,000
Q2 2018 Sep 14, 2018	SELL	$50.53 - $62.98 $169,174 - $210,857	-3,348 Closed	0 $0
Q1 2018 Sep 14, 2018	BUY	$59.92 - $68.98 $200,612 - $230,945	3,348 New	3,348 $212,000
Q4 2017 Sep 14, 2018	SELL	$59.94 - $65.35 $318,041 - $346,747	-5,306 Closed	0 $0
Q3 2017 Sep 14, 2018	BUY	$55.23 - $63.74 $165 - $191	3 Added 0.06%	5,306 $338,000
Q2 2017 Sep 13, 2018	SELL	N/A	-178 Reduced 3.25%	5,303 $295,000
Q1 2017 Sep 13, 2018	SELL	N/A	-97 Reduced 1.74%	5,481 $298,000
Q4 2016 Sep 13, 2018	BUY	N/A	203 Added 3.78%	5,578 $326,000
Q3 2016 Sep 13, 2018	BUY	N/A	1,346 Added 33.41%	5,375 $290,000
Q2 2016 Sep 13, 2018	BUY	N/A	4,029 New	4,029 $296,000
Q1 2016 Sep 13, 2018	SELL	N/A	-2,945 Closed	0 $0
Q4 2015 Sep 13, 2018	BUY	N/A	2,945	2,945 $203,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Steigerwald, Gordon & Koch Inc., based on Form 13F filings with the SEC.

Stay updated on Steigerwald, Gordon & Koch Inc. with notifications on news.